Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tysabri Could Return To Market As “Niche” Drug, Analyst Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Morgan Stanley report predicts sales of $500 mil. for Biogen Idec/Elan’s multiple sclerosis therapy if it returns to market. Analyst’s review shows additional safety signals.

You may also be interested in...

Tysabri Safety Data To Be Submitted To FDA This Fall, Biogen Idec/Elan Say

Biogen Idec and Elan will complete a Tysabri safety review by late summer in the hopes of bringing the multiple sclerosis therapy back on the market.

Tysabri Withdrawal Prompts Biogen Idec To Suspend Financial Guidance

Company plans to issue revised guidance in May after warning investors not to rely on previous financial forecasts. Announcement coincides with news that a third diagnosis of PML was discovered in a clinical trial for Tysabri.

Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts